Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer

Pharmacogenetics and Genomics

Volumn 22, Issue 2, 2012, Pages 105-116

  Li, Liang ^a   Schaid, Daniel J ^b   Fridley, Brooke L ^b   Kalari, Krishna R ^b   Jenkins, Gregory D ^b   Abo, Ryan P ^a   Batzler, Anthony ^b   Moon, Irene ^b   Pelleymounter, Linda ^b   Eckloff, Bruce W ^a   Wieben, Eric D ^a   Sun, Zhifu ^b   Yang, Ping ^b   Wang, Liewei ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b Department of Health Sciences Research ^*  (United States)

Author keywords

gemcitabine; lymphoblastoid cell line; metabolic pathway; non small cell lung cancer; pharmacogenomics

Indexed keywords

5' NUCLEOTIDASE; CYTIDINE DEAMINASE; DNA; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MEMBRANE PROTEIN; PHARMACOLOGICAL BIOMARKER; PROTEIN SLC28A3; PROTEIN SLC29A1; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; LUNG NON SMALL CELL CANCER; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84855932882     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834dd7e2     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Peto R, Chen ZM, Boreham J. Tobacco: the growing epidemic. Nat Med 1999; 5:15-17.
3. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, Inc; 2010.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360. (Pubitemid 38101630)
5. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024. (Pubitemid 46606280)
6. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465. (Pubitemid 28309041)
7. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130. (Pubitemid 30036345)
8. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317-323. (Pubitemid 46323100)
9. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291. (Pubitemid 35266288)
10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98. (Pubitemid 34438899)
11. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18. (Pubitemid 29022372)
12. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 20,20-difluorodeoxycytidine 50-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52:533-539.
13. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 20,20-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48:4024-4031.
14. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5):v7-v12. (Pubitemid 43994854)
15. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23:3-15. (Pubitemid 26362189)
16. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008; 23:379-384.
17. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, et al. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 2006; 21:248-256.
18. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, et al. Ribonucleotide reductase M1 (RRM1) 2464G< A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16:429-438. (Pubitemid 43804800)
19. Maring JG, Groen HJ,Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005; 5:226-243. (Pubitemid 41131715)
20. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42. (Pubitemid 350003048)
21. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620-2624. (Pubitemid 40569462)
22. Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, et al. Cytosolic 50-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet Genomics 2009; 19:567-576.
23. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12:1794-1803.
24. Ji Y, Olson J, Zhang J, Hildebrandt M,Wang L, Ingle J, et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 2008; 68:5997-6005.
25. Moyer AM, Sun Z, Batzler AJ, Li L, Schaid DJ, Yang P, et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinumbased chemotherapy. Cancer Epidemiol Biomarkers Prev 2010; 19: 811-821.
26. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008; 68:7050-7058.
27. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010; 20:1482-1492.
28. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128:452-462. (Pubitemid 40994510)
29. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008; 168: 1097-1103. (Pubitemid 351749227)
30. Kocabas NA, Aksoy P, Pelleymounter LL, Moon I, Ryu JS, Gilbert JA, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008; 36:1951-1959.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434. (Pubitemid 34112296)
32. De Bakker PI, Yelensky R, Pé er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1217-1223. (Pubitemid 41568704)
33. Li Y,Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34:816-834.
34. Clark AG. The role of haplotypes in candidate gene studies. Genet Epidemiol 2004; 27:321-333. (Pubitemid 39602317)
35. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009; 4:e7765.
36. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-1073.
37. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447:735-743.
38. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349-4357. (Pubitemid 28450036)
39. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-1825. (Pubitemid 44884058)
40. Hunsucker SA, Mitchell BS, Spychala J. The 50-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005; 107:1-30. (Pubitemid 40800406)
41. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 2006; 75:681-706. (Pubitemid 44118048)
42. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41:77-88.
43. Muller PJ, Dally H, Klappenecker CN, Edler L, Jager B, Gerst M, et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009; 124:1669-1674.
44. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65:512-519. (Pubitemid 38264018)
45. Soo RA,Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63:121-127.
46. Stark AL, ZhangW, Mi S, Duan S, O'Donnell PH, Huang RS, et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J 2010; 10:505-512.
47. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, De Jager PL, et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 2008; 4:e1000287.
48. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010; 28:4674-4682.
49. Ingle JN, Liu M, Wickerham DL, Schaid DJ, Mushiroda T, Kubo M, et al. Genome-wide associations of breast events and functional genomics studies in high-risk women receiving tamoxifen or raloxifene on NSABP P1 and P2 prevention trials: a pharmacogenomics research network-RIKENNSABP collaboration. Cancer Res 2010; 70:110 s.
50. Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, et al. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res 2011; 17:3830-3840.
51. Pankratz VS, Sun Z, Aakre J, Li Y, Johnson C, Garces YI, et al. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. J ThoracOncol 2011; 6:1488-1495.
52. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447:728-734. (Pubitemid 38241458)